GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seer Inc (NAS:SEER) » Definitions » ROE %

Seer (SEER) ROE % : -17.74% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Seer ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Seer's annualized net income for the quarter that ended in Dec. 2023 was $-71.20 Mil. Seer's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $401.29 Mil. Therefore, Seer's annualized ROE % for the quarter that ended in Dec. 2023 was -17.74%.

The historical rank and industry rank for Seer's ROE % or its related term are showing as below:

SEER' s ROE % Range Over the Past 10 Years
Min: -27.26   Med: -20.01   Max: -12.62
Current: -20.54

During the past 6 years, Seer's highest ROE % was -12.62%. The lowest was -27.26%. And the median was -20.01%.

SEER's ROE % is ranked better than
66.81% of 1362 companies
in the Biotechnology industry
Industry Median: -44.1 vs SEER: -20.54

Seer ROE % Historical Data

The historical data trend for Seer's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seer ROE % Chart

Seer Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -27.26 -12.62 -15.23 -19.57 -20.45

Seer Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.92 -21.78 -22.02 -20.48 -17.74

Competitive Comparison of Seer's ROE %

For the Biotechnology subindustry, Seer's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seer's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seer's ROE % distribution charts can be found below:

* The bar in red indicates where Seer's ROE % falls into.



Seer ROE % Calculation

Seer's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-86.277/( (446.993+396.904)/ 2 )
=-86.277/421.9485
=-20.45 %

Seer's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-71.196/( (405.679+396.904)/ 2 )
=-71.196/401.2915
=-17.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Seer  (NAS:SEER) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-71.196/401.2915
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-71.196 / 16.72)*(16.72 / 440.561)*(440.561 / 401.2915)
=Net Margin %*Asset Turnover*Equity Multiplier
=-425.81 %*0.038*1.0979
=ROA %*Equity Multiplier
=-16.18 %*1.0979
=-17.74 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-71.196/401.2915
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-71.196 / -71.196) * (-71.196 / -88.928) * (-88.928 / 16.72) * (16.72 / 440.561) * (440.561 / 401.2915)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.8006 * -531.87 % * 0.038 * 1.0979
=-17.74 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Seer ROE % Related Terms

Thank you for viewing the detailed overview of Seer's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Seer (SEER) Business Description

Traded in Other Exchanges
N/A
Address
3800 Bridge Parkway, Suite 102, Redwood City, CA, USA, 94065
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access across the proteome.
Executives
Elona Esq. Kogan officer: General Counsel and Secretary C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Omid Farokhzad director, 10 percent owner, officer: CEO and Chair of the Board C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Scott D Thomas officer: Chief Commercial Officer C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
David R. Horn officer: Chief Financial Officer 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Omead Ostadan director, officer: President & COO C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Meeta Gulyani director C/O SEER, INC., 3800 BRIDGEPOINT PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Rachel E. Haurwitz director C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Maverick Ventures Investment Fund, L.p. director 300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
Maverick Capital Ventures, Llc director 300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
Maverick Advisors Fund, L.p. director 300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
David Hallal director C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Terrance Mcguire director C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
David B Singer director C/O MAVERICK CAPITAL, LTD., 101 CALIFORNIA STREET, SUITE 4015, SAN FRANCISCO CA 94111
Cathy Friedman director C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005

Seer (SEER) Headlines

From GuruFocus

Seer to Report First Quarter Financial Results on May 4, 2022

By GuruFocusNews GuruFocusNews 04-07-2022

Seer to Present at the Cowen 43rd Annual Health Care Conference

By sperokesalga sperokesalga 02-21-2023